DF
CORT icon

DecisionPoint Financial’s Corcept Therapeutics CORT Stock Holding History

DecisionPoint Financial’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$444 Hold
11
– – ﹤0.01% 504
2025
Q4 		$383 Hold
11
– – ﹤0.01% 589
2025
Q3 		$927 Hold
11
– – ﹤0.01% 345
2025
Q2 		$763 Buy
+11
New +$798 ﹤0.01% 363

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

DecisionPoint Financial's CORT Position: Q1 2026 in Review

DecisionPoint Financial held its Corcept Therapeutics (CORT) position steady in Q1 2026 at 11 shares worth $444. The position accounts for ﹤0.01% of the portfolio, ranked #504.

DecisionPoint Financial first reported a position in CORT in Q2 2025 and has held it in 4 quarters since. The position peaked at $927 in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • DecisionPoint Financial held 11 shares of Corcept Therapeutics worth $444 as of Q1 2026.
  • DecisionPoint Financial left its Corcept Therapeutics share count unchanged in Q1 2026.
  • Corcept Therapeutics made up ﹤0.01% of DecisionPoint Financial's portfolio in Q1 2026, its #504 holding.
  • DecisionPoint Financial first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • DecisionPoint Financial's Corcept Therapeutics position peaked at $927 in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on DecisionPoint Financial's 13F filing for Q1 2026, filed 6 May 2026.